Cristina Ripoll - Infectious Diseases

Author Information

Dr. Cristina Ripoll is affiliated with the Clinic for Internal Medicine IV: Gastroenterology, Hepatology, Infectious Diseases and Interdisciplinary Endoscopy at Friedrich-Schiller University in Jena, Germany. Her research primarily focuses on the field of hepatology, with particular interest in cirrhosis, portal hypertension, and related complications. Dr. Ripoll's extensive work in this domain has significantly contributed to the understanding and management of liver diseases.

Research Contributions

Dr. Ripoll has an impressive portfolio of research contributions, with recent papers highlighting critical aspects of liver disease management. In 2022, she contributed to the EASL Clinical Practice Guidelines on bleeding and thrombosis in cirrhosis patients, a testament to her expertise in this area. Her research also delves into the implications of transjugular intrahepatic portosystemic shunt (TIPS) procedures and the role of machine learning in predicting cirrhosis decompensation. The recurrent theme across her publications is the optimization of therapeutic strategies and improving patient outcomes in liver disease.

Aliases

Dr. Cristina Ripoll is also known by the names C Ripoll and C. Ripoll. These aliases appear in various publications and citations, reflecting the common practice of using abbreviated forms in academic authorship.

Publication and Citation Metrics

Metric	Value
Number of Papers	178
Total Citation Count	8808
H-index	46

Publications:

EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis.

DOI: 10.1016/j.jhep.2021.09.003

Year: 2022

Corrigendum to 'Baveno VII - Renewing consensus in portal hypertension' [J Hepatol (2022) 959-974].

DOI: 10.1016/j.jhep.2022.03.024

Year: 2022

Lack of porto-caval gradient (PCG) increase after transjugular intrahepatic portosystemic shunt (TIPS) implantation under deep sedation is associated to poor survival

DOI: 10.1055/s-0041-1740722

Year: 2022

Machine learning models predicting decompensation in cirrhosis

DOI: 10.1055/s-0041-1740706

Year: 2022

Baveno VII - Renewing consensus in portal hypertension.

DOI: 10.1016/j.jhep.2021.12.022

Year: 2021

First things first! Can bacterial infections be considered as decompensating events per se?

DOI: 10.1016/j.jhep.2021.05.030

Year: 2021

Protective Effects of Statin Therapy in Cirrhosis Are Limited by a Common SLCO1B1 Transporter Variant

DOI: 10.1002/hep4.1753

Year: 2021

Isolated bacterial infection without decompensation has no impact on survival of compensated patients with cirrhosis

DOI: 10.1111/liv.14842

Year: 2021

Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data.

DOI: 10.1053/j.gastro.2020.09.026

Year: 2020

The bone marrow pool of megakaryocytes and their ability to proliferate are preserved in rats with advanced cirrhosis

DOI: 10.1016/s0168-8278(20)30926-0

Year: 2020

Is Vaccination Available?

How Does the FDA Ensure the Safety of Antiviral Drugs?

What are Immunodeficiency Disorders?

Can Inherited Immunity Be Enhanced?

Why is Hygiene Important in Infectious Diseases?

How is Lyme Disease Transmitted?

Are There Specific Hygiene Recommendations for Food Safety?

How is Dengue Transmitted?

Why is Mosquito Control Crucial?

What is Neonatal Conjunctivitis?

Partnered Content Networks

Relevant Topics